Insulin analogues: Fears, facts and fantasies

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue 1, 2009, Pages 50-51

  Cordera, Renzo ^a   Salani, Barbara ^a   Briatore, Lucia ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN DERIVATIVE; INSULIN RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; CARCINOGEN; DRUG DERIVATIVE; INSULIN; TERATOGENIC AGENT;

BINDING AFFINITY; BREAST ADENOCARCINOMA; CANCER CELL; CARCINOGENIC ACTIVITY; CELL PROLIFERATION; COLORECTAL CANCER; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; ARTICLE; DIABETES MELLITUS; FEMALE; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION;

CARCINOGENS; DIABETES COMPLICATIONS; FEMALE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; PREGNANCY; PREGNANCY COMPLICATIONS; TERATOGENS;

EID: 65549110163     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.934     Document Type: Note

References (10)

1. Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem 2008; 114: 3-10.
2. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I like mitogenic and antiapoptotic activities in cultured cancer cells DMRR 2008.
3. Staiger K, Staiger H, Schweitzer MA, et al. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 2005; 48: 898-905.
4. Liefvendahl E, Arnqvist HJ. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 2008; 40: 369-74.
5. Erbel S, Reers C, Eckstein VW, et al. Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 2008; 31: 1105-11.
6. Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 2002; 21: 171-9.
7. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008; 114: 38-44.
8. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
9. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; CD005613.
10. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006; CD003287.